Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 9 Mar 2012 |
| Zealand Pharma and Helsinn announce the advance of elsiglutide into Phase II for the prevention of chemotherapy-induced diarrhea in cancer patients | 2 Mar 2012 |
| Zealand Pharma’s Annual General Meeting 2012 | 27 Feb 2012 |
| Zealand Pharma A/S New warrant program - New Articles of Association | 23 Feb 2012 |
| Zealand Pharma A/S establishes a warrant program for the employees of the company | 10 Feb 2012 |
| Zealand Pharma to present at 2012 BIO CEO Investor Conference | 10 Feb 2012 |